THE LONG-TERM IMPACT OF BEDAQUILINE-CONTAINING REGIMENS ON COST BURDEN OF DRUG-RESISTANT TUBERCULOSIS IN INDIA

被引：0
|
作者：
Agnarson, M. A. [1 ]
Potluri, R. [2 ]
Bhandari, H. [3 ]
Dhir, A. [4 ]
Kumar, A. [3 ]
Gupta, V [5 ]
Raute, L. [5 ]
Shah, N. [5 ]
Kambili, C. [6 ]
Metz, L. [1 ]
机构：
[1] Johnson & Johnson, New Brunswick, NJ USA
[2] SmartAnalyst Inc, New York, NY USA
[3] SmartAnalyst India Pvt Ltd, Gurgaon, India
[4] SmartAnalyst India Pvt Ltd, Gurgaon, HR, India
[5] Janssen India, Mumbai, Maharashtra, India
[6] Johnson & Johnson, South Raritan, NJ USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN48
引用
收藏
页码：S648 / S648
页数：1
相关论文
共 50 条
  • [41] LONG-TERM LINEZOLID TREATMENT IN A YOUNG CHILD WITH EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS
    Schaaf, H. Simon
    Willemse, Marianne
    Donald, Peter R.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (08) : 748 - 750
  • [42] LONG-TERM OUTCOMES OF PATIENTS WITH EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS IN THE COUNTRY OF GEORGIA
    Frank, M.
    Adamashvili, N.
    Lomtadze, N.
    Kokhreidze, E.
    Avaliani, Z.
    Kempker, R. R.
    Blumberg, H. M.
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2018, 66 (02) : 577 - 577
  • [43] Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19
    Solodovnikova, Varvara
    Kumar, Ajay M., V
    Hurevich, Hennadz
    Sereda, Yuliia
    Auchynka, Vera
    Katovich, Dzmitry
    Klimuk, Dzmitry
    Skrahin, Aliaksandr
    Setkina, Svetlana
    Charnysh, Iryna
    Yedilbayev, Askar
    Skrahina, Alena
    [J]. MONALDI ARCHIVES FOR CHEST DISEASE, 2021, 91 (01)
  • [44] Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK
    Wolfson, Lara J.
    Walker, Anna
    Hettle, Robert
    Lu, Xiaoyan
    Kambili, Chrispin
    Murungi, Andrew
    Knerer, Gerhart
    [J]. PLOS ONE, 2015, 10 (03):
  • [45] Comparison of linezolid regimens, in addition to bedaquiline and pretomanid, for the management of drug-resistant tuberculosis (the ZeNix study): Critical reading
    Zela-Coila, Frank
    Cabrera-Cruzado, Carlos
    Baquerizo-Quispe, Nicole Stephanie
    Alvarez-Vilchez, Margarita Liz
    Taype-Rondan, Alvaro
    [J]. REVISTA DEL CUERPO MEDICO DEL HOSPITAL NACIONAL ALMANZOR AGUINAGA ASENJO, 2023, 16 (02):
  • [46] The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa
    Agnarson, Abela Mpobela
    Williams, Abeda
    Kambili, Chrispin
    Mattson, Gunnar
    Metz, Laurent
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2020, 18 (05) : 475 - 483
  • [47] Case series of the long-term psychosocial impact of drug-resistant tuberculosis in HIV-negative medical doctors
    Padayatchi, N.
    Daftary, A.
    Moodley, T.
    Madansein, R.
    Ramjee, A.
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2010, 14 (08) : 960 - 966
  • [48] Concomitant bedaquiline and delamanid therapy in patients with drug-resistant extra-pulmonary tuberculosis in Mumbai, India
    Mongia, Himani
    Mamnoon, Fatima
    Silsarma, Arunima
    Mahajan, Raman
    Dalal, Alpa
    Galindo, Miriam Arago
    Iyer, Aparna
    Singh, Pramila
    Mansoor, Homa
    Das, Mrinalini
    Morales, Mabel
    Spencer, Hannah
    Isaakidis, Petros
    [J]. JOURNAL OF CLINICAL TUBERCULOSIS AND OTHER MYCOBACTERIAL DISEASES, 2024, 35
  • [49] In vivo evolution of drug-resistant Mycobacterium tuberculosis in patients during long-term treatment
    Yuhui Xu
    Fei Liu
    Suting Chen
    Jiannan Wu
    Yongfei Hu
    Baoli Zhu
    Zhaogang Sun
    [J]. BMC Genomics, 19
  • [50] In vivo evolution of drug-resistant Mycobacterium tuberculosis in patients during long-term treatment
    Xu, Yuhui
    Liu, Fei
    Chen, Suting
    Wu, Jiannan
    Hu, Yongfei
    Zhu, Baoli
    Sun, Zhaogang
    [J]. BMC GENOMICS, 2018, 19
12345